VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Aug 21, 2008 -- Chemokine Therapeutics Corp. (the "Company") (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908. The Company received FDA and Health Canada approval for the clinical trial earlier this year.

The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.

"Liver cancer is more prevalent in the Asian communities and working with Dr. Ronnie Poon, Principal Investigator for Hong Kong, will help to expedite the patient recruitment process," stated Walter Korz, President and Chief Executive Officer of the Company.

The Company also wishes to announce that Fundamental Research Corporation (FRC) has initiated analyst coverage of the Company. Information on FRC is available at www.researchfrc.com.

About Chemokine Therapeutics Corp. (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News)

Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the Company's ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

     Contacts:
     Chemokine Therapeutics Corp.
     Mr. Don Evans
     Vice President, Corporate Communications
     (604) 738-6643 or 1-888-822-0305
     (604) 738-6645 (FAX)
     Email: devans@chemokine.net
     Website: http://www.chemokine.net